Sanofi (NASDAQ:SNY) Shares Sold by Hotchkis & Wiley Capital Management LLC

Hotchkis & Wiley Capital Management LLC cut its holdings in Sanofi (NASDAQ:SNY) by 1.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,258,430 shares of the company’s stock after selling 31,120 shares during the quarter. Hotchkis & Wiley Capital Management LLC owned about 0.09% of Sanofi worth $130,153,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of SNY. HighTower Advisors LLC increased its stake in shares of Sanofi by 1.0% in the third quarter. HighTower Advisors LLC now owns 88,100 shares of the company’s stock valued at $5,081,000 after buying an additional 848 shares during the period. Hilltop Holdings Inc. lifted its stake in shares of Sanofi by 47.9% in the third quarter. Hilltop Holdings Inc. now owns 10,224 shares of the company’s stock worth $589,000 after buying an additional 3,313 shares in the last quarter. Cinctive Capital Management LP raised its holdings in Sanofi by 106.6% during the third quarter. Cinctive Capital Management LP now owns 155,109 shares of the company’s stock worth $8,939,000 after purchasing an additional 80,033 shares in the last quarter. Benjamin Edwards Inc. purchased a new stake in shares of Sanofi during the 3rd quarter worth $991,000. Finally, Bellevue Group AG acquired a new stake in shares of Sanofi in the third quarter worth approximately $871,000. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Down 1.1 %

SNY opened at $47.96 on Tuesday. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a market cap of $121.71 billion, a P/E ratio of 24.47, a PEG ratio of 1.23 and a beta of 0.58. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The business’s 50-day simple moving average is $52.80 and its 200-day simple moving average is $52.15.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same period in the prior year, the firm earned $2.55 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. As a group, equities research analysts expect that Sanofi will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on SNY shares. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.